Actavis sells off Chinese subsidiary


Generic drugs heavyweight Actavis is selling off a subsidiary based in Foshan, China. The business is being bought by Zhejiang Chiral Medicine Chemicals for an undisclosed sum.

In a company statement, Actavis stressed that the company ‘intends to continue further commercial operations in China in collaboration with its preferred business partners’. But in an interview with Bloomberg, chief executive Paul Bisaro claimed that doing business in China is ‘too risky’, and the returns were not worth the effort compared to other markets.


Related Content

UCB sells speciality generics subsidiary

26 November 2014 Business

news image

Firm will use $1.5bn proceeds to reduce debt and concentrate on developing new drugs in neurology and immunology

Riding new waves

6 January 2015 Business

news image

Pharmaceutical industry roundup of 2014

Most Read

Collaboration, not competition

29 June 2015 Research

news image

Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom

Copper catalysis overcomes double bond trouble

3 July 2015 Research

news image

Stubbornly stable unactivated internal alkenes become chiral tertiary amine precursors

Most Commented

Collaboration, not competition

29 June 2015 Research

news image

Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom

Z machine puts the squeeze on metallic deuterium

25 June 2015 Research

news image

Pressures similar to those at centre of the Earth forge metallic deuterium in step toward 80-year-old dream of creating metal...